ArticleBlood cancer discovery2021
Determinants of response and mechanisms of resistance of CAR T-cell therapy in multiple myeloma.
Article in Blood cancer discovery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed.
- Clinical evaluation and determinants of response to HBI0101 (BCMA CART) therapy in relapsed/refractory multiple myeloma.Blood advances · 2024Trial
- Randomized Phase II Trial of Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance after Upfront Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: BMT CTN 1401.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Trial
- Multiple Myeloma Cells Resistant to T-cell Therapies Exhibit a CD45+ Immunoevasive Phenotype.Cancer immunology research · 2026Article
- Transcriptomic landscape of peripheral T cells following CAR-T cell therapy in diffuse large B cell lymphoma.Cancer immunology, immunotherapy : CII · 2026Article
- Advances in immune microenvironment profiling during multiple myeloma progression and therapy.International journal of hematology · 2026Review
- The Shape-Shifting Myeloma: Adaptive Plasticity as a Hallmark of Relapse and Refractoriness.Cancers · 2026Review
- Genomic profiling enables personalized strategies to overcome drug resistance in multiple myeloma.Discover oncology · 2026Review
- The cellular orchestra of CAR T success.Cancer cell · 2026Article
- Article
- Mechanisms and intervention strategies of microenvironment-mediated drug resistance in multiple myeloma.Cancer cell international · 2026Review
- Advancing CAR-T therapy in multiple myeloma: a critical appraisal of CARTITUDE-4 and the path toward earlier lines.Frontiers in oncology · 2026Article
- Cross-modal fusion of cytomorphology andFrontiers in immunology · 2026Article
- Antibody-Drug Conjugates, T-Cell Engager Bispecific Antibodies and Chimeric Antigen Receptor T Cells for Multiple Myeloma: What's the Current Status?Targeted oncology · 2026Review
- Redefining Cure in Multiple Myeloma: Are We Chasing a Moving Target?Health science reports · 2025Article
- The endogenous T cell landscape is reshaped by CAR-T cell therapy and predicts treatment response in multiple myeloma.Leukemia · 2025Article
- Expanding Immunotherapy Beyond CAR T Cells: Engineering Diverse Immune Cells to Target Solid Tumors.Cancers · 2025Review
- Evaluating therapeutic plasma exchange and protease inhibitors as mechanisms to reduce soluble mesothelin.Scientific reports · 2025Article
- Deciphering response dynamics and treatment resistance from circulating tumor DNA after CAR T-cells in multiple myeloma.Nature communications · 2025Article
- Review
- Genetic disruption of Blimp-1 drastically augments the antitumor efficacy of BCMA-targeting CAR T cells.Blood advances · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
BCMA-specific CAR T-cells have substantial therapeutic potential in multiple myeloma (MM), but most patients eventually relapse. Determinants of response and mechanisms of resistance are most likely multifactorial and include MM-related factors, premanufacturing T-cell characteristics, CAR T-cell-related features, and several components of the immunosuppressive microenvironment. Efforts to improve the potency and safety of CAR T-cell therapy include optimizing CAR design, combinatorial approaches to enhance persistence and activity, treatment of less heavily pretreated patients, and dual-antigen targeting to prevent antigen escape. We expect that these rationally designed strategies will contribute to further improvement in the clinical outcome of MM patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.